BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Twinpig Biolab\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Twinpig Biolab\, Inc.'s drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06400160-2758@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TB511: Phase 1/2 readout est. (NCT06400160)
DESCRIPTION:TB511\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Clinica
 l Trial of TB511 in Advanced Solid Tumors\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tb511#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06400160
URL:https://assetmemo.bio/drug/tb511#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
